A Phase II Trial of PTK-787 [vatalanib] in Recurrent or Progressive Meningiomas.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2018
At a glance
- Drugs Vatalanib (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Oct 2014 Status changed from active, no longer recruiting to completedas as reported by ClinicalTrials.gov.
- 21 Mar 2013 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.